A growing number of cases of acute kidney injury in patients taking one of the type 2 diabetes medications canagliflozin (Invokana, Invokamet) or dapagliflozin (Farxiga, Xigudo XR) have prompted the Food and Drug Administration (FDA) to strengthen the current warnings on the drugs. Canagliflozin and dapagliflozin are in a class of type 2 diabetes drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. They are used along with diet and exercise to lower blood sugar levels in adults with type 2 diabetes. The drugs work by causing the kidneys to remove sugar from the body and excrete it through the urine. ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.